Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ELOXX PHARMACEUTICALS : Financial Statements and Exhibits (form 8-K/A)

06/16/2021 | 04:12pm EDT

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired

Zikani's audited financial statements as of and for the years ended December 31, 2020 and 2019 and the related notes, as well as Zikani's unaudited condensed financial statements as of and for the three months ended March 31, 2021 and the related notes are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K/A and incorporated herein by reference.

(b) Pro Forma Financial Information

The unaudited pro forma condensed consolidated financial statements of the Company as of and for the three months ended March 31, 2021 and the related notes are attached as Exhibit 99.3 to this Current Report on Form 8-K/A and incorporated herein by reference.




(c) Exhibits:



Exhibit No.   Description

  23.1          Consent of Moody, Famiglietti & Andronico, LLP, Independent
              Registered Public Accounting Firm

  99.1          Zikani Therapeutics, Inc. audited financial statements as of and for
              the years ended December 31, 2020 and 2019

  99.2          Zikani Therapeutics, Inc. unaudited condensed financial statements
              as of and for the three months ended March 31, 2021

  99.3          Unaudited pro forma condensed consolidated financial statements of
              Eloxx Pharmaceuticals, Inc.

104           Inline XBRL for the cover page of this Current Report on Form 8-K

© Edgar Online, source Glimpses

All news about ELOXX PHARMACEUTICALS, INC.
07/16ELOXX PHARMACEUTICALS : Corporate Controller, Treasurer Resigns
MT
07/16ELOXX PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-..
AQ
07/16Gary Rakers to Resign as Executive Director, Finance & Accounting, Corporate ..
CI
07/06ELOXX PHARMACEUTICALS : Provides Enrollment Update for Ongoing Phase 2 Clinical ..
PU
07/06ELOXX PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regulat..
AQ
07/06Eloxx Pharmaceuticals, Inc. Announces the departure of Neil Belloff as Chief ..
CI
07/06ELOXX PHARMACEUTICALS : Pharma Expects Part of Mid-Stage Cystic Fibrosis Trial D..
MT
07/06Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical..
GL
07/06Eloxx Pharmaceuticals, Inc. Provides Enrollment Update for Ongoing Phase 2 Cl..
CI
06/30ELOXX PHARMACEUTICALS : Mizuho Securities Starts Eloxx Pharmaceuticals at Buy Wi..
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -32,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,30x
Yield 2021 -
Capitalization 118 M 118 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 25
Free-Float 90,4%
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | ELOX | US29014R1032 | MarketScreener
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,37 $
Average target price 3,78 $
Spread / Average Target 176%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Tomer Kariv Chairman
Thomas P. Haverty Chief Medical Officer
Vijay Modur Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-65.58%179
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-26.46%32 170
SEAGEN INC.-16.87%28 525